Vaccine Info

INO-A002 Zika

Inovio's proprietary platform is leading the way forward for activation immunotherapy.

This one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual's immune system to generate a robust targeted T cell and antibody response.

As of February 20, 2019, Inovio Pharmaceuticals, Inc. in collaboration with The Wistar Institute and the University of Pennsylvania announced today that the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody (dMAb™) technology.

Funded fully by the Bill & Melinda Gates Foundation, this trial's focus is on evaluating the dMAb's, INO-A002 ability to prevent or treat Zika virus infection.

This open-label trial is a single center, dose escalation trial that will enroll up to 24 healthy volunteers who will receive up to four doses of INO-A002.

The trial is led by Pablo Tebas, M.D., Professor of Medicine at the Hospital of the University of Pennsylvania.

Clinical Trial NCT03831503:  A Phase 1 Study of INO-A002 in Healthy Dengue Virus-naive Adults

Updated
May 17th, 2019